# US 2012/0252031 A1 · Compositions and methods for regulating sas1r

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252031 A1
- Document ID: US20120252031A1
- Status: Published application
- Kind: A1
- Application number: 13/479,167
- Filed: 2012-05-23
- Published: 2012-10-04
- Earliest claimed: 2005-02-23
- Assignees: University of Virginia Patent Foundation
- Inventors: John C. Herr; Monika Sachdev; Arabinda Mandal
- Web page: https://patentgrep.com/patent/US20120252031A1

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 38/1709: {from mammals}
- A61K 38/177: {Receptors; Cell surface antigens; Cell surface determinants}
- A61K 38/4886: {Metalloendopeptidases (3.4.24), e.g. collagenase}
- A61K 39/0006: {Contraceptive vaccins; Vaccines against sex hormones}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N 2333/96486: Metalloendopeptidases (3.4.24)
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention provides compositions and methods useful for regulating fertilization and for use as a contraceptive based on the discovery herein of an oocyte specific protein, SAS1R (Sperm Acrosomal SLLP1 Receptor), which is a sperm protein receptor. Six SAS1R variants, including the full length SAS1R, were identified. mSLLP1 and SAS1R co-localized to oocytes and to acrosomes of acrosome-reacted sperm. Interactions between mSLLP1 and SAS1R were demonstrated by far-western analysis, in a yeast two-hybrid system under stringent selection conditions, and by immunoprecipitation of SAS1R by anti-mSLLP1 as well as the converse. Purified recombinant SAS1R was found to have protease activity, to inhibit fertilization in-vitro, and to induce an immune response in females. Together, the results suggest SAS1R is a proteolytically active, oocyte and early embryo specific oolemmal metalloprotease receptor for the sperm intra-acrosomal ligand SLLP1 and is a target for regulating fertilization and as a contraceptive.

## Claims

### Claim at position 1

-17. (canceled)

### Claim 18

A method of identifying a compound which is an inhibitor of SAS1R, an immunogenic oocyte stage specific metalloprotease sperm protein receptor, further wherein inhibition of SAS1R is reversible and inhibits fertilization, said method comprising:
a. adding a test compound to a test sample comprising SAS1R;
b. analyzing the level of SAS activity in said test sample with the level of SAS1R activity in an otherwise identical sample comprising SAS1R not subjected to a test compound;
c. wherein a lower level of SAS activity in said test sample subjected to a test compound compared with the level of SAS1R activity in said otherwise identical sample is an indication that said test compound is an inhibitor of SAS1R; and
d. thereby identifying a compound which is an inhibitor of SAS1R.

### Claim 19 (depends on 18)

The method of claim 18, wherein said SAS1R activity is protease activity.

### Claim 20 (depends on 18)

The method of claim 18, wherein said SAS1R activity is interaction with a SLLP protein.

### Claim 21 (depends on 18)

The method of claim 18, wherein said compound inhibits fertilization.

### Claim 22 (depends on 18)

The method of claim 18, wherein said compound is a protein, or a fragment or homolog thereof.

### Claim 23 (depends on 22)

The method of claim 22, wherein said protein, or a fragment or homolog thereof has a sequence selected from the group consisting of SEQ ID NOs:6, 8, 10, 19, 20, 21, and 23, or a fragment or homolog thereof.

### Claim at position 8

-25. (canceled)

### Claim 26 (depends on 20)

The method of claim 20, wherein said SAS1R function is protease activity.

### Claim 27 (depends on 22)

The method of claim 22, wherein said compound is an antibody.

### Claim 28 (depends on 27)

The method of claim 27, wherein the antibody is directed against a SAS1R sequence selected from the group consisting of SEQ ID NOs:6, 8, 10, 19, 20, 21, and 23, or a fragment or homolog thereof.

### Claim 29 (depends on 27)

The method of claim 27, wherein said antibody is selected from the group consisting of a polyclonal antibody, a monoclonal antibody, a chimeric antibody, and a synthetic antibody.

### Claim 30 (depends on 27)

The method of claim 27, wherein said antibody binds to about amino acids 1-120 of an amino acid sequence selected from the group consisting of SEQ ID NOs:6, 8, 10, 19, 20, 21, and 23.

### Claim 31 (depends on 18)

The method of claim 18, wherein said test sample comprises a sperm and an egg.

### Claim 32 (depends on 31)

The method of claim 31, wherein said inhibitor of SAS1R inhibits sperm and egg fusion.

### Claim 33 (depends on 18)

The method of claim 18, wherein said test sample comprises a protease assay.

### Claim 34 (depends on 20)

The method of claim 20, wherein said interaction of SAS1R and SLLP is measured by an assay selected from the group consisting of far-western, Biacore SPR, co-immunoprecipitation, co-localization, yeast two-hybrid, and in vitro fertilization.

### Claim at position 18

-58. (canceled)
